Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. A phase I dose-escalation ...
These high attrition rates compared with those of other therapeutic areas can be explained in part by particular characteristics of oncology drugs, 4 including a narrow therapeutic index, complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results